Abstract:Rationale: Wear particle-induced periprosthetic osteolysis (PPO) is a common long-term complication of total joint arthroplasty, and represents the major cause of aseptic loosening and subsequent implant failure. Previous studies have identified the central role of osteoclast-mediated bone resorption in the pathogenesis of PPO. Thus, therapeutic approaches of inhibiting osteoclast formation and activity are considered to be of great potential to prevent and treat this osteolytic disease. Hedgehog (Hh) signaling has been shown to play an important role in promoting osteoblast differentiation and bone formation. While Hh signaling is also implicated in regulating osteoclastogenesis, whether it can directly inhibit osteoclast differentiation and bone resorption remains controversial. Moreover, its potential therapeutic effects on PPO have never been assessed. In this study, we explored the cell-autonomous role of Hh signaling in regulating osteoclastogenesis and its therapeutic potential in preventing wear particle-induced osteolysis. Methods: Hh signaling was activated in macrophages by genetically ablating Sufu in these cells using LysM-Cre or by treating them with purmorphamine (PM), a pharmacological activator of Smoothened (Smo). In vitro cell-autonomous effects of Hh pathway activation on RANKL-induced osteoclast differentiation and activity were evaluated by TRAP staining, phalloidin staining, qPCR analyses, and bone resorption assays. In vivo evaluation of its therapeutic efficacy against PPO was performed in a murine calvarial model of titanium particle-induced osteolysis by mu CT and histological analyses. Mechanistic details were explored in RANKL-treated macrophages through Western blot analyses. Results: We found that Sufu deletion or PM treatment potently activated Hh signaling in macrophages, and strongly inhibited RANKL-induced TRAP(+) osteoclast production, F-actin ring formation, osteoclast-specific gene expression, and osteoclast activity in vitro. Furthermore, we found that Sufu deletion or PM administration significantly attenuated titanium particle-induced osteoclast formation and bone loss in vivo. Our mechanistic study revealed that activation of Hh signaling suppressed RANKL-induced activation of JNK pathway and downregulated protein levels of two key osteoclastic transcriptional factors, c-Fos and its downstream target NFATc1. Conclusions: Both genetic and pharmacological activation of Hh signaling can cell-autonomously inhibit RANKL-induced osteoclast differentiation and activity in vitro and protect against titanium particle-induced osteolysis in vivo. Mechanistically, Hh signaling hinders osteoclastogenesis partly through suppressing the JNIQc-Fos-NFATc1 cascade. Thus, Hh signaling may serve as a promising therapeutic target for the prevention and treatment of PPO and other osteolytic diseases.

Stevioside Prevents Wear Particle-Induced Osteolysis by Inhibiting Osteoclastogenesis and Inflammatory Response via the Suppression of TAK1 Activation.

Platelet-Derived Growth Factor-Bb Attenuates Titanium-Particle-Induced Osteolysis in Vivo

Stevioside attenuates osteoarthritis via regulating Nrf2/HO-1/NF-κB pathway

Sophocarpine Attenuates Wear Particle‐induced Implant Loosening by Inhibiting Osteoclastogenesis and Bone Resorption Via Suppression of the NF‐κB Signalling Pathway in a Rat Model

The Prevention of Titanium-Particle-induced Osteolysis by OA-14 Through the Suppression of the P38 Signaling Pathway and Inhibition of Osteoclastogenesis.

Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.

Modulating Autophagy by Strontium-Doped Micro/nano Rough Titanium Surface for Promotion of Osteogenesis and Inhibition of Osteoclastogenesis.

Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade.

Strontium Ranelate Inhibits Titanium-Particle-Induced Osteolysis, by Restraining Inflammatory Osteoclastogenesis in Vivo

LY450139 Inhibited Ti-Particle-Induced Bone Dissolution via Suppressing Notch and NF-κB Signaling Pathways

Calycosin alleviates titanium particle‐induced osteolysis by modulating macrophage polarization and subsequent osteogenic differentiation

Stevioside protects primary articular chondrocytes against IL-1β-induced inflammation and catabolism by targeting integrin

Effects of the Local Bone Renin-Angiotensin System on Titanium-Particle-Induced Periprosthetic Osteolysis

Curculigoside Protects against Titanium Particle-Induced Osteolysis through the Enhancement of Osteoblast Differentiation and Reduction of Osteoclast Formation

Lycorine Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents Ovariectomy-Induced Osteoporosis and Titanium Particle-Induced Osteolysis in Vivo

Hydrogen Sulfide Protects Against Particle‐induced Inflammatory Response and Osteolysis Via SIRT1 Pathway in Prosthesis Loosening

Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib in Vivo

Rhoifolin ameliorates titanium particle‐stimulated osteolysis and attenuates osteoclastogenesis via RANKL‐induced NF‐κB and MAPK pathways

Effects of blood pH and carbon dioxide on cerebral electrical activity

Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells

Effects of Sequential Treatment with Intermittent Parathyroid Hormone and Zoledronic Acid on Particle-Induced Implant Loosening: Evidence from a Rat Model